3,867 reports of this reaction
4.4% of all FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE reports
#3 most reported adverse reaction
ASTHMA is the #3 most commonly reported adverse reaction for FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE, manufactured by GlaxoSmithKline LLC. There are 3,867 FDA adverse event reports linking FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE to ASTHMA. This represents approximately 4.4% of all 88,399 adverse event reports for this drug.
Patients taking FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE who experience asthma should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ASTHMA is moderately reported among FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE users, representing a notable but not dominant share of adverse events.
In addition to asthma, the following adverse reactions have been reported for FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE:
The following drugs have also been linked to asthma in FDA adverse event reports:
ASTHMA has been reported as an adverse event in 3,867 FDA reports for FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ASTHMA accounts for approximately 4.4% of all adverse event reports for FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE, making it one of the most commonly reported side effect.
If you experience asthma while taking FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.